Gene · 10765
Papers2,218
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 2,218
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| KDM5B recruits FOXG1 to suppress the IFN response, leading to malignant progression and immune evasion in cervical cancer. | Front Med (Lausanne) | 2026 | 41994447 | PubTator, text mining | PubMed |
| MicroLive: an image processing toolkit for quantifying live-cell single-molecule microscopy. | Bioinform Adv | 2026 | 41994225 | PubTator, text mining | PubMed |
| Shared and distinct effects of mood stabilizers on epigenetic machinery gene expression: an exploratory study in HeLa cells. | Eur Neuropsychopharmacol | 2026 | 41955765 | PubTator, text mining | PubMed |
| Multi‑omics and their integration in psoriasis research (Review). | Mol Med Rep | 2026 | 41891974 | PubTator, text mining | PubMed |
| Monoallelic and biallelic KDM5A variants identified in patients with autism spectrum disorder. | HGG Adv | 2026 | 41889174 | PubTator, text mining | PubMed |
| Noncanonical role of KDM5C in conferring bortezomib resistance via the PERK‒Nrf2 axis in multiple myeloma. | Cell Death Dis | 2026 | 41872155 | PubTator, text mining | PubMed |
| The JMJD family histone demethylases: structure, mechanism of action, diseases and therapeutic targets. | Mol Biomed | 2026 | 41857315 | PubTator, text mining | PubMed |
| Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer. | Signal Transduct Target Ther | 2026 | 41813651 | PubTator, text mining | PubMed |
| Transdermal siRNA delivery via biomineralized nanoparticle-incorporated microneedles modulates cuproptosis-ferroptosis interaction for psoriasis therapy. | Mater Today Bio | 2026 | 41809386 | PubTator, text mining | PubMed |
| Signaling network inhibition by selected traditional Chinese medicine preparations: a novel multi-target paradigm for colorectal cancer therapy. | Front Pharmacol | 2026 | 41800081 | PubTator, text mining | PubMed |
| Structural and Functional Validation of Pseudomonas Savastanoi Ethylene Forming Enzymes Reveals Flexibility in 2-Oxoglutarate Binding Mode and Conformation. | Chembiochem | 2026 | 41797450 | PubTator, text mining | PubMed |
| KDM5D expression is lost in cisplatin‑resistant neuroblastoma cells. | Oncol Rep | 2026 | 41789643 | PubTator, text mining | PubMed |
| KDM5B-driven glucose metabolic reprogramming promotes enzalutamide resistance in prostate cancer via the lactate/hnRNPA1 lactylation/AR-V7 axis. | Mol Cancer | 2026 | 41787526 | PubTator, text mining | PubMed |
| The role of KDM5B in creating synthetic vulnerabilities in combination with radiotherapy in melanoma cells. | Cell Commun Signal | 2026 | 41787437 | PubTator, text mining | PubMed |
| Identification of prognostic genes associated with tolerogenic dendritic cells in gastric cancer based on transcriptomic data. | PLoS One | 2026 | 41785223 | PubTator, text mining | PubMed |
| Nucleosome spacing across cell types, diseases, and ages. | Nucleic Acids Res | 2026 | 41784266 | PubTator, text mining | PubMed |
| Single-cell advances in the investigation of the pathogenesis and treatment of brain metastasis. | Neurooncol Adv | 2026 | 41769415 | PubTator, text mining | PubMed |
| Dual-Piezo-Charge Strategy in (1-0)-3 Single-Crystal Composite for Enhancing Underwater Acoustic Sensing. | Nanomicro Lett | 2026 | 41762341 | PubTator, text mining | PubMed |
| Ferroptosis as a Novel Therapeutic Strategy to Overcome Multidrug Resistance in Colorectal Cancer. | Pharmaceuticals (Basel) | 2026 | 41754792 | PubTator, text mining | PubMed |
| Evidence that extra copies of chromosome 1q play a role in the early phases of pancreatic neoplasia. | Sci Adv | 2026 | 41719404 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10765/papers?page=2